The purpose of the proposed project is to determine if short-term dietary supplementation of magnesium will improve performance during a series of lab-based exercise tests, will favorably modify the gut-microbiota, and will augment skeletal muscle mitochondrial function.
Magnesium is the fourth most abundant mineral in the human body. It is critical to day-to-day physiological function including the regulation of metabolism, cardiovascular function, immune function, and the operation of the nervous system. In light of its important role in physiology, dietary supplementation of magnesium has been purported to improve athletic performance, although the precise mechanism is unclear. The foci of the proposed study is the ergogenic effects of magnesium, its potential influence on gut health, and its potential ability to improve skeletal muscle function. The investigators will be studying an athletic/competitive population of endurance-trained adults. This group is likely to be the most interested in the use of magnesium to enhance athletic performance. Also, by only recruiting habitual exercisers, the variability between participants is likely to be reduced compared with if the investigators had also recruited people who are usually sedentary.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
41
Colorado State University, Dept. of Health and Exercise Science
Fort Collins, Colorado, United States
Comparison of completion of time trial to placebo
Amount of time it takes to cycle 10 kilometers
Time frame: After 9 days of intervention
Comparison of power output to placebo
Cycling for 30 seconds
Time frame: After 9 days of intervention
Comparison of indirect Calorimetry (VO2max) to placebo
During a standard stress test VO2 max will be measured
Time frame: After 8 days of intervention
Comparison of lactate threshold to placebo
During a standard stress test lactate threshold will be measured
Time frame: After 8 days of intervention
Comparison of Mitochondrial Function to placebo
Assessed via high-resolution mitochondrial respirometry in permeabilized skeletal muscle.
Time frame: After 8 days of intervention
Comparison of Shannon and Faith's microbiota diversity scores in feces to placebo
Assessed via 16s ribosomal ribonucleic acid microbial profiling
Time frame: After 9 days of intervention,
Calculation and ordination of B-diversity scores for all fecal samples to assess clustering
Assessed via 16s ribosomal ribonucleic acid microbial profiling
Time frame: After 9 days of intervention
Determination of differentially abundant microbiota in feces of collected during treatment compared to placebo
Assessed via 16s ribosomal ribonucleic acid microbial profiling
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: After 9 days of intervention
Comparison of abundant microbiota to markers in feces to placebo
Assessed via Linear discriminant analysis Effect Size algorithm
Time frame: After 9 days of intervention
Comparison Human Granulocyte Macrophage Colony-Stimulating Factor to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interferon gamma to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 1 beta to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 2 to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 4 to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 5 to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 6 to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 7 to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 8 to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 10 to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 12 (p70) to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison interleukin 13 to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison Tumor Necrosis Factor alpha to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention
Comparison High-sensitivity C-reactive protein to placebo
Assessed via 13-plex human T-cell cytokine panel
Time frame: After 9 days of intervention